Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00539-17. doi: 10.1128/AAC.00539-17. Print 2017 Jul.

Anti-influenza Activity of a Bacillus subtilis Probiotic Strain.

Author information

1
Gromashevsky Institute of Epidemiology and Infectious Diseases, National Academy of Medical Sciences of Ukraine, Kiev, Ukraine.
2
Institute of Microbiology and Virology, National Academy of Sciences, Kiev, Ukraine.
3
Department of Anatomy, Physiology and Pharmacology, Auburn University, Auburn, Alabama, USA sorokib@auburn.edu.

Abstract

Among Bacillus bacteria, B. subtilis is the species that produces the most antimicrobial compounds. In this study, we analyzed the activity of probiotic strain B. subtilis 3 against the influenza virus. The antiviral effect of this strain has been demonstrated in vitro and in vivo A new peptide, P18, produced by the probiotic strain was isolated, purified, chemically synthesized, and characterized. Cytotoxicity studies demonstrated no toxic effect of P18 on Madin-Darby canine kidney (MDCK) cells, even at the highest concentration tested (100 μg/ml). Complete inhibition of the influenza virus in vitro was observed at concentrations of 12.5 to 100 μg/ml. The protective effect of P18 in mice was comparable to that of oseltamivir phosphate (Tamiflu). Further study will assess the potential of peptide P18 as an antiviral compound and as a promising candidate for the development of new antiviral vaccines.

KEYWORDS:

Bacillus subtilis; antiviral peptide; influenza virus; probiotics

PMID:
28416546
PMCID:
PMC5487639
DOI:
10.1128/AAC.00539-17
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center